



Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.
www.lilly.com

Fecha: **12 de Julio de 2017**

NOTA DE PRENSA

Eli Lilly and Company presentará más de 40 Abstracts en la Alzheimer's Association International Conference® 2017 (AAIC® 2017)

Entre los datos destacados se incluyen resultados en salud que enfatizan la necesidad del diagnóstico a tiempo y el abordaje adecuado de la enfermedad de Alzheimer

Indianápolis (Estados Unidos), 12 de julio de 2017.– Eli Lilly and Company (NYSE: LLY) ha anunciado hoy que presentará los resultados de más de 40 estudios de investigación en la próxima Conferencia Internacional de la Asociación de Alzheimer® 2017 (AAIC® 2017) que se celebra en Londres del 16 al 20 de julio de 2017. Los datos destacan la amplia cartera de fármacos en desarrollo para el Alzheimer de Lilly, que incluyen potenciales tratamientos y fármacos de diagnóstico en diferentes etapas de desarrollo clínico, además de los resultados de salud sobre el uso de los recursos sanitarios antes del diagnóstico de la enfermedad de Alzheimer.

“La investigación ha demostrado que la enfermedad de Alzheimer comienza a desarrollarse años antes de que aparezcan los síntomas que repercuten en las actividades diarias. Para combatir eficazmente esta enfermedad, las personas con Alzheimer, sus cuidadores y sus médicos necesitan mantener un diálogo más productivo antes, con el objetivo de reconocer y diagnosticar la enfermedad lo antes posible”, afirmó Phyllis Ferrell, vicepresidenta del equipo de la Plataforma de Alzheimer de Lilly. “Mantenemos nuestro compromiso de encontrar soluciones para la enfermedad de Alzheimer y creemos que hay nuevas terapias prometedoras en el horizonte”.

De particular interés resulta una presentación oral que puede ayudar a fundamentar el cuidado futuro de la enfermedad de Alzheimer:

- **Trends in Health Service Use and Potentially Avoidable Hospitalizations Prior to Alzheimer's Disease Diagnosis: A Matched, Retrospective Study of US Medicare Beneficiaries** *Oral presentation, Thursday, July 20, 12:00PM – 12:15PM. Presenting author: JS Andrews*

Además, se presentarán los siguientes estudios (todos en horario de Inglaterra):

Datos de Solanezumab

- **Plasma Pharmacokinetics and Pharmacodynamics of Solanezumab in Mild and Moderate AD Patients** *Poster presentation, Sunday, July 16, 9:30AM- 4:15PM. Presenting author: B Willis*

- **The Basics of Fluid Biomarkers in Alzheimer’s Disease: Standardization, Quality Control and Regulatory Issues for Fluid Biomarkers** *Educational workshop, Friday, July 14, 8:00AM – 5:00PM. Presenting author: RA Dean*
- **Solanezumab Central Target Engagement and Pharmacodynamic Activity in the EXPEDITION 3 Trial of Patients with Mild AD: Comparison to EXPEDITION/EXPEDITION 2** *Poster presentation, Sunday, July 16, 9:30AM – 4:15PM. Presenting author: J Raskin*
- **Deriving a Cut-Off for the Elecsys® β -Amyloid (1–42) Immunoassay for Use in Clinical Trials Supported by Eli Lilly for Patients with Clinically Defined Alzheimer’s Disease** *Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: L. Shaw*
- **Effect of Solanezumab on Biomarkers of Neurodegeneration in the EXPEDITION3 Trial in Mild Alzheimer Disease** *Poster presentation, Saturday, July 15, 12:15PM – 1:30PM. Presenting author: AJ Schwarz*
- **Safety of Solanezumab in Phase 3 Studies in Individuals with Mild Alzheimer’s Disease Dementia** *Poster presentation, Sunday, July 16, 9:30AM – 4:15PM. Presenting author: C Carlson*
- **Contemporary Issues in Clinical Trials Methods: Delayed Start Analysis in Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease** *Educational workshop, Friday, July 14, 8:00AM – 5:00PM. Presenting author: H Liu-Seifert*
- **Comparison of Baseline ARIA-H Prevalence at 1.5T and 3T MRI Field Strengths in a Multi-Site Global Clinical Trial with Cohort of 2137 AD Subjects** *Poster presentation, Sunday, July 16, 9:30AM – 4:15PM. Presenting author: A Schwarz*
- **The Integrated Alzheimer’s Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial** *Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: A Wessels*
- **The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision-Making** *Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: KE Bullok*
- **Big Pharma in VCID: What Will It Take?** *Featured research session, Wednesday, July 19, 5:15PM – 5:35PM. Presenting author: J Sims*

Datos sobre Neurodegeneración

- **Establishing Microfluidic Devices As an in Vitro Neuronal Model for Studying Molecular and Functional Aspects of Transneuronal Tau Propagation** *Poster presentation, Tuesday, July 18, 9:30AM – 4:15PM. Presenting author: A Katsikoudi*
- **Investigating Glymphatic Function during Early Tau Pathology Using Dynamic Contrast-Enhanced MRI** *Poster presentation, Saturday, July 15, 12:15PM – 1:30PM. Presenting author: O Ismail*

- **The Coalition Against Major Diseases: Towards U.S. FDA Qualification of Hippocampal Volume As a Biomarker for Enrichment in Clinical Trials for Pre-Dementia Stages of Alzheimer's Disease** *Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: D Conrado*
- **Regulated Release of HYPER-Phosphorylated, Aggregated and Seeding Competent Tau from BRAIN Rodent and Human Synaptosomes** *Oral presentation, Sunday, July 16, 3:00PM – 3:15PM. Presenting author: E Sher*
- **Plasma Total Tau, Cognitive Decline, and Risk of Mild Cognitive Impairment in the Mayo Clinic Study on Aging** *Poster presentation, Tuesday, July 18, 9:30AM – 4:15PM. Presenting author: M Mielke*
- **Characterisation of Molecular Mechanisms That Are Triggered and Contribute to Tau Pathology in a Cell Model of Tau Aggregation** *Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: J Wolak*
- **fMRI of Visual Stimuli in a Tau Model of Alzheimer's Disease** *Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: I Harrison*
- **In Vivo Two-Photon Imaging of the Effects of Tauopathy and Amyloidopathy on Synapses** *Poster presentation, Tuesday, July 18, 9:30AM – 4:15PM. Presenting author: J Jackson*
- **Developing In Vivo models of Tau Propagation Which Are Relevant to Human Disease Pathogenesis and Applicable to Pre-Clinical Drug Discovery** *Oral presentation, Tuesday, July 18, 2:15PM – 2:30PM. Presenting author: Z Ahmed*
- **An Academic-Private Partnership for the Validation of New Models to Understand Tau-Related Hyperexcitability & Aggregation Using Human Induced Pluripotent Stem Cells** *Poster presentation, Tuesday, July 18, 9:30AM – 4:15PM. Presenting author: AC Socorro*
- **Characterization of Biofluid sTREM2 Using a Novel sTREM2 Assay** *Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: H Wang*
- **Assessing TREM2 Function in Alzheimer's Disease with RNA-Seq** *Oral presentation, Monday, July 17, 5:30PM – 5:45PM. Presenting author: G Carbajosa*

Datos sobre Moduladores de Depósito de la proteína Tau

- **Aggregate-Selective Anti-Tau Antibody MC-1 Demonstrated Robust in Vitro and In Vivo Activity to Neutralize Transmissible Tau and Reduce Tau Pathology** *Oral presentation, Monday, July 17, 5:00PM – 5:15PM. Presenting author: M Hayashi*
- **Preclinical Characterization of an Antibody [LY3303560] Targeting Aggregated Tau** *Oral presentation, Monday, July 17, 5:15PM – 5:30PM. Presenting author: R Alam*

- **Preclinical in Vitro and In Vivo Characterization of Tau Antibodies to Block Tau Propagation**
Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: S Wu

Datos sobre la molécula FabPEG

- **Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Subjects of Single Doses of LY2599666, an Antigen Binding Fragment (Fab) of a Monoclonal Antibody That Targets Soluble Monomer A β Linked to a Poly(ethylene glycol) Molecule**
Poster presentation, Sunday, July 16, 9:30AM – 4:15PM. Presenting author: AM Hake

Datos sobre el trazador diagnóstico Flortaucipir

- **A Robust, Simplified Braak-Type Classification Scheme for Flortaucipir F 18 Tau PET Images**
Oral presentation, Saturday, July 15, 9:45AM – 10:00AM. Presenting author: AJ Schwarz
- **The Association of Tau Burden in Cerebral Lobes and Functional Brain Networks with Performance in Different Cognitive Domains**
Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: A Charil
- **Comparison of Regional Flortaucipir PET to Quantitative Tau and Amyloid Immunoassay in Patients with Alzheimer's Disease Pathology: A Pilot Clinico-Pathological Study**
Poster presentation, Monday, July 17, 9:30AM – 4:15PM. Presenting author: AD Siderowf
- **An Update on the Binding Profile of Flortaucipir in AD Versus Normal CNS Proteins and Normal Brain**
Oral presentation, Sunday, July 16, 3:15PM – 3:30PM. Presenting author: G Attardo
- **Parametric Imaging of Tau Load in Alzheimer's Patients and Controls Using Flortaucipir**
Poster presentation, Saturday, July 15, 12:15PM – 1:30PM. Presenting author: EE Wolters
- **Pathology in the Early Alzheimer's Prodrome: Self and Informant Cognitive Concerns Show Different Patterns of Association with Tau Deposition on [18f]Flortaucipir PET in Amyloid Positive Older Adults**
Poster presentation, Saturday, July 15, 12:15PM – 1:30PM. Presenting author: S Risacher
- **PET Biomarkers in the EXPEDITION 3 Trial of Patients with Mild AD**
Oral presentation, Thursday, July 20, 8:30AM – 8:45AM. Presenting author: MA Mintun
- **Modeling of Tau Trajectories across the Alzheimer's Disease Spectrum Using [18F]-Flortaucipir PET Imaging**
Poster presentation, Wednesday, July 19, 9:30AM – 4:15PM. Presenting author: S Shcherbinin

Datos Generales de la Enfermedad de Alzheimer

- **Intermediate Changes in Cognition Predict Long Term Outcomes in Mild Alzheimer's Disease Dementia** *Poster presentation, Monday, July 17, 9:30AM – 4:15PM. Presenting author: C Reed*
- **Is the Annual Wellness Visit Adequate to Impact Cognitive Care?** *Poster presentation, Tuesday, July 18, 9:30AM – 4:15PM. Presenting author: N Fowler*

Datos del Anticuerpo monoclonal Selectivo AB 1-42

- **Preclinical Discovery and Development of MEDI1814, a Monoclonal Antibody Selectively Targeting Beta-Amyloid 42 (A β 42)** *Poster presentation, Sunday, July 16, 9:30AM – 4:15PM. Presenting author: A Billinton*
- **MEDI1814, a High-Affinity Antibody Directed to the C-Terminus of A β x-42, Abrogates Synaptic Plasticity Disruption Caused By Synthetic or AD Brain-Derived A β Soluble Assemblies In Vivo** *Poster presentation, Tuesday, July 18, 9:30AM – 4:15PM. Presenting author: T Ondrejcek*
- **Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814, a beta-Amyloid 42 (ab42)-Specific Antibody, in Patients with Mild-Moderate Alzheimer's Disease** *Oral presentation, Monday, July 17, 2:15PM – 2:30PM. Presenting author: T Ostefeld*

Sobre la enfermedad de Alzheimer

La enfermedad de Alzheimer es una enfermedad que causa un deterioro progresivo en la memoria y otros aspectos de la cognición así como de las capacidades funcionales y de autocuidado que finalmente llevan al fallecimiento del paciente. La demencia causada por la enfermedad de Alzheimer es la forma más común de demencia, representando entre el 60 y el 80 por ciento de todos los casos^{1,2}. Actualmente se estima que hay 47 millones de personas con demencia en todo el mundo, ¹ cifras que se espera aumenten a casi 75 millones en 2030 y 132 millones en 2050.¹ Cada año, se diagnostican casi 10 millones nuevos de casos de demencia en todo el mundo, lo que significa que cada 3,2 segundos se produce un nuevo diagnóstico.¹ El coste social y económico anual actual de la demencia se estima en más de 800.000 millones de dólares y se espera que se convierta en una enfermedad de mil millones de dólares para 2018³.

Sobre Eli Lilly and Company

Lilly es un líder global de la atención sanitaria que une pasión con descubrimiento para mejorar la vida de las personas en todo el mundo. Nuestra compañía fue fundada hace más de un siglo por un hombre comprometido a fabricar medicinas de gran calidad que atienden necesidades reales. Hoy seguimos siendo fieles a esa misión en nuestro trabajo. En todo el mundo los empleados de Lilly trabajan para descubrir y ofrecer medicinas vitales a aquellos que las necesitan, mejorar la comprensión y el tratamiento de la enfermedad y contribuir a las comunidades a través de la acción social y el voluntariado. Si desea más información sobre Lilly, visítenos en www.lilly.com y www.lilly.es

Referencias:

- ¹ Alzheimer's Disease International. Dementia statistics. <http://www.alz.co.uk/research/statistics>. Accessed March 2017.
- ² Alzheimer's Association. What Is Dementia? <http://www.alz.org/what-is-dementia.asp>. Accessed March 2017.
- ³ Alzheimer's Disease International. World Alzheimer Report 2015 The Global Impact of Dementia. <https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf>. Accessed March 2017.

#

Este comunicado de prensa contiene declaraciones prospectivas (como dicho término se define en la Ley de Reforma de Litigios de Valores Privados de 1995) sobre tratamientos de investigación y diagnósticos para la enfermedad de Alzheimer y refleja la creencia actual de Lilly. Sin embargo, como con cualquier producto farmacéutico, hay riesgos e incertidumbres sustanciales en el proceso de desarrollo y comercialización. Entre otras cosas, no puede garantizarse que los resultados de los estudios futuros sean coherentes con los resultados obtenidos hasta la fecha o que estos compuestos o diagnósticos de investigación alcancen los criterios de valoración del estudio primario o reciben aprobaciones reglamentarias. Para más información sobre estos y otros riesgos e incertidumbres, vea las presentaciones más recientes de Formulario 10-K y Form 10-Q de Lilly con la Comisión de Valores y Bolsa de los Estados Unidos. Excepto por lo requerido por la ley, Lilly no se obliga a actualizar las declaraciones prospectivas para reflejar los eventos posteriores a la fecha de este comunicado.